Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 3Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × temsirolimus × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡